Top Back to top

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Study number:
2013-003831-31
Type of transplant:
 
Short title:
MK8228
Study status:
Recruiting
Deadline for data collection:
 
Study design:
Prosepctive, randomised, placebo controlled, mulit site, double blind
Primary objective:
To evaluate the efficacy of MK-8228 in the prevention of clinically significant CMV infection through Week 24 (~6 months) post-transplant following administration of MK-8228 or placebo.
Key inclusion criteria:
 
Country:
Austria
Belgium
Brazil
Canada
Finland
France
Germany
Italy
Japan
Lithuania
New Zealand
Peru
Poland
Romania
South Korea
Spain
Sweden
Turkey
United Kingdom
United States
Principal investigator:
 
Principal investigator email:
 
EBMT Study coordinator:
Sue Philpott

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org